Page last updated: 2024-12-05
di-n-octyl phthalate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
di-n-octyl phthalate: plasticizer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 8346 |
| CHEMBL ID | 1409747 |
| CHEBI ID | 34679 |
| SCHEMBL ID | 23053 |
| MeSH ID | M0056435 |
Synonyms (77)
| Synonym |
|---|
| BIDD:ER0319 |
| LS-15074 |
| bis(n-octyl) phthalate |
| vinicizer 85 |
| 1, dioctyl ester |
| phthalic acid, dioctyl ester |
| 117-84-0 |
| dioctyl 1,2-benzenedicarboxylate |
| di-n-octyl phthalate |
| nsc-15318 |
| nsc15318 |
| n-octyl phthalate |
| dinopol nop |
| dioctyl o-benzenedicarboxylate |
| 1,2-benzenedicarboxylic acid, dioctyl ester |
| NCGC00090781-01 |
| 1,2-benzenedicarbonic acid, dioctyl ester |
| brn 1915994 |
| dnop |
| rcra waste no. u107 |
| einecs 204-214-7 |
| dioktylester kyseliny ftalove [czech] |
| benzenedicarboxylic acid di-n-octyl ester |
| nsc 15318 |
| hsdb 1345 |
| rcra waste number u107 |
| ai3-15071 (usda) |
| ccris 6196 |
| dioctyl phthalate |
| NCGC00090781-02 |
| di-n-octyl phthalate, >=98.0% (gc) |
| dioctyl benzene-1,2-dicarboxylate |
| FT-0667608 |
| FT-0655747 |
| phthalic acid di-n-octyl ester |
| P0304 |
| 8031-29-6 |
| A803836 |
| NCGC00090781-03 |
| NCGC00090781-04 |
| 8x3rj0527w , |
| dioktylester kyseliny ftalove |
| unii-8x3rj0527w |
| 1,2-benzenedicarboxylic acid, 1,2-dioctyl ester |
| tox21_300549 |
| tox21_202233 |
| NCGC00259782-01 |
| NCGC00254360-01 |
| cas-117-84-0 |
| tox21_111020 |
| dtxcid801956 |
| dtxsid1021956 , |
| STL280370 |
| AKOS015889916 |
| di-n-octyl phthalate [hsdb] |
| di-octyl phthalate |
| SCHEMBL23053 |
| CHEBI:34679 , |
| NCGC00090781-05 |
| vinycizer 85 |
| dioctyl o-phthalate |
| CHEMBL1409747 |
| J-003672 |
| J-520376 |
| di-n-octyl phthalate, certified reference material, tracecert(r) |
| F0001-0293 |
| mfcd00015292 |
| di-n-octyl phthalate, analytical standard |
| di-n-octyl phthalate, p.a., 99% |
| phthalic acid, bis-n-octyl ester |
| di-n-octylphthalate |
| Q908490 |
| EN300-40135 |
| 1,2-dioctyl benzene-1,2-dicarboxylate |
| Z407875554 |
| is_di-n-octyl phthalate-3,4,5,6-d4 |
| o-benzenedicarboxylicacid dioctylester |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " DHPP and DnOP had no adverse effect on maternal feed consumption and body weight gain, or on the incidence of post-implantation loss and fetal body weight." | ( Prenatal developmental toxicity studies on di-n-heptyl and di-n-octyl phthalates in Sprague-Dawley rats. Gallissot, F; Roudot, AC; Sabaté, JP; Saillenfait, AM, 2011) | 0.61 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Adjuvant effect was accepted to be present if a statistical increase in antibody production occurred in a test group as compared to an ovalbumin control group together with the fulfillment of dose-response relationships." | ( Adjuvant effect of di-n-butyl-, di-n-octyl-, di-iso-nonyl- and di-iso-decyl phthalate in a subcutaneous injection model using BALB/c mice. Larsen, ST; Lund, RM; Nielsen, GD; Poulsen, OM; Thygesen, P, 2002) | 0.31 |
| " The influences of the adsorbent dosage and the use frequency of adsorbent, the adsorption time, the solution pH and ionic strength were investigated and optimized." | ( Dispersive Micro-Solid-Phase Extraction Based on Decanoic Acid Coated-Fe₃O₄ Nanoparticles for HPLC Analysis of Phthalate Esters in Liquor Samples. Wang, J; Xin, D; Yang, Y; Zhang, L, 2015) | 0.42 |
| " Besides, comet assay indicated that there was a dose-response relationship between the DNA damage and phthalate dose, following DMP > DOP > BBP." | ( Phthalate induced oxidative stress and DNA damage in earthworms (Eisenia fetida). Gao, J; Li, X; Song, P; Wang, J; Zhang, C; Zhu, L, 2019) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
| Class | Description |
|---|---|
| phthalate ester | |
| diester | A diester is a compound containing two ester groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (22)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 2.7223 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
| AR protein | Homo sapiens (human) | Potency | 23.7082 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID743042; AID743054; AID743063 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 25.1189 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 19.4594 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 2.3919 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 5.4386 | 0.0002 | 14.3764 | 60.0339 | AID720691; AID720692 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 6.8380 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 8.9125 | 0.3758 | 27.4851 | 61.6524 | AID588527 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 68.3804 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 30.1922 | 0.0002 | 29.3054 | 16,493.5996 | AID588514; AID743069; AID743075 |
| G | Vesicular stomatitis virus | Potency | 3.0112 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 54.7730 | 0.0010 | 19.4141 | 70.9645 | AID743094 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 0.0013 | 0.0237 | 23.2282 | 63.5986 | AID588543 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 35.4813 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 43.1451 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 4.3641 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 0.0014 | 0.0100 | 39.5371 | 1,122.0200 | AID588547 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 12.5893 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| Interferon beta | Homo sapiens (human) | Potency | 3.0112 | 0.0033 | 9.1582 | 39.8107 | AID1645842 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 3.0112 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 3.0112 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 3.0112 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (45)
Molecular Functions (18)
Ceullar Components (22)
Bioassays (4)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (56)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 8 (14.29) | 18.7374 |
| 1990's | 3 (5.36) | 18.2507 |
| 2000's | 8 (14.29) | 29.6817 |
| 2010's | 26 (46.43) | 24.3611 |
| 2020's | 11 (19.64) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 39.76
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (39.76) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (1.69%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 58 (98.31%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||